key: cord-0760664-yxz3rvak authors: Conticini, Edoardo; d'Alessandro, Miriana; Bergantini, Laura; Bargagli, Elena; Gentili, Francesco; Mazzei, Maria Antonietta; Cantarini, Luca; Frediani, Bruno title: Relapse of microscopic polyangiitis after vaccination against COVID‐19: A case report date: 2021-07-20 journal: J Med Virol DOI: 10.1002/jmv.27192 sha: 68eadd60cc763df52489b037ed0d0978e241fd9b doc_id: 760664 cord_uid: yxz3rvak After the approval of the first vaccines against SARS-CoV-2, a mass vaccination is currently being performed worldwide. Despite the safety and efficacy of such drugs evidenced by the registration studies, no clinical trial has to date included patients affected by autoimmune diseases nor data coming from real life are currently available. In this regard, we report the case of a patient affected by microscopic polyangiitis who suspended Methotrexate prior to vaccination and relapsed after the administration of the first dosage. The patient required hospitalization and was treated with high dosages of steroids but was rapidly discharged in good clinical condition. Our case evidences that the immune response triggered by the administration of the vaccine against COVID 19 may reactivate autoimmune disorders, but such condition seems manageable and the withdrawal of the immunosuppressants should not be performed. This article is protected by copyright. All rights reserved. In this regard, we report the case of a 77-year-old male, who presented with necrotic ulcers of the lower limbs in September 2020. In August he had suffered an acute episode of mild-to-moderate dyspnea, followed by hematuria and lower limb purpura. Dyspnea and hematuria resolved rapidly after self-administration of glucocorticoids, whereas purpura worsened, eventually leading to large ulcers. Blood chemistry showed slight elevation of C-reactive protein (CRP) and serum creatinine, while urinalysis showed proteinuria and hemoglobinuria. Autoimmunity blood tests were all negative, whereas skin biopsy was compatible with leukocytoclastic vasculitis. A diagnosis of microscopic polyangiitis was eventually made and the patient was treated with prednisone, tapered slowly to 6.25 mg/day, and methotrexate (MTX) 15 mg/week, which led to prompt and complete resolution of skin involvement. After 4 months of treatment, the patient, by now considered to be in remission, was called for vaccination against COVID-19 and he decided to temporarily suspend MTX. A few days after the first shot of BioNtech/Pfizer Comirnaty, he experienced severe, rapidly worsening dyspnea and presented at the emergency unit. Arterial blood gas analysis showed severe hypoxemia (pO 2 48 mm Hg) and low oxygen saturation, while blood chemistry showed elevation of CRP It is well known that many autoimmune rheumatic diseases may be triggered by infectious stimuli, particularly viruses. 4 Another major trigger may be vaccines themselves: vaccines may even trigger different subsets of diseases, particularly in immune-compromised and/or elderly subjects. 5 It is therefore not surprising that SARS-CoV-2 may trigger the development and/or relapse of certain autoimmune disorders, including vasculitis. To the best of our knowledge, few papers have reported cases of COVID-induced vasculitis in adulthood: these have usually concerned IgA-related, 6,7 antineutrophil cytoplasmic antibodies (ANCA)-associated, 8, 9 or large-vessel forms. [10] [11] [12] Presentation may be extremely variable and, in cases of lung involvement, the differential diagnosis between idiopathic vasculitis and COVID-19 may be challenging. 8, 9 On the other hand, there have not yet been any reports of cases of patients whose rheumatic condition has worsened or even relapsed after vaccination against COVID-19. The present case report describes the first immune-related adverse event due to Comirnaty in a rheumatic patient considered to be in remission. Relapse presented without skin involvement, but with severe worsening of lung involvement, leading to immediate hospitalization and oxygen therapy. Fortunately, recovery was rapid, and the patient did not require any immunosuppressants other than glucocorticoids. This case shows that the immune response elicited by vaccination against COVID-19 may reactivate autoimmune disorders such as vasculitis. The physiopathological mechanisms have not been fully understood; nevertheless, we may hypothesize that vaccination, through the production of antibodies against SARS-CoV2 spike glycoprotein, eventually cross-reacting against host peptides, 13 may trigger pre-existing aberrant immune mechanisms. 14 In the case of ANCA-associated vasculitis, auto-antibodies production, and neutrophils and complement activation both lead to vascular damage and vasculitis relapse. The presentation may be severe and require hospitalization, but symptoms seem to be manageable with conventional treatments. Further data from larger cohorts will provide more robust evidence for the prevention and treatment of immune-related adverse events of COVID-19 vaccines. The withdrawal of MTX may have been a factor in unleashing the vasculitis and an aberrant immune response in our patient. As already suggested by available guidelines, 3 it may therefore be advisable not to suspend immunosuppressants, before vaccination. No funding was received for this study. The authors declare that there are no conflicts of interest. The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Greek Rheumatology Society and Professional Association of Rheumatologists (ERE-EPERE). Vaccination against SARS-CoV-2 in immunosuppressed patients with rheumatic diseases: position statement of the Greek Rheumatology Society Impfung gegen SARS-CoV-2 bei entzündlich rheumatischen erkrankungen: empfehlungen der DGRh für Ärzte und patienten [Vaccination against SARS-CoV-2 in inflammatory rheumatic diseases: recommendations of the German Society for view points on SARS-CoV-2 vaccination in patients with RMDs Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener's granulomatosis) Polymyalgia rheumatica following infective triggers or vaccinations: a different subset of disease? A child with Henoch-Schonlein purpura secondary to a COVID-19 infection COVID-19-related IgA vasculitis New onset granulomatosis with polyangiitis associated with COVID-19 Eosinophilic pulmonary vasculitis as a manifestation of the hyperinflammatory phase of COVID-19 Case of adult large vessel vasculitis after SARS-CoV-2 infection Florid aortitis following SARS-CoV-2 infection Vasculitis and aortitis: COVID-19 challenging complications Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases COVID-19 vaccine and autoimmunity: awakening the sleeping dragon